Those taking Bydureon (Exenatide) and similar Type-2 Diabetes medications are exposed to the risks of developing pancreatitis and thyroid cancer. According the the American Diabetes Association, a recent study involving 20 diabetics showed a 40% increase in pancreatic cells and cell damage in patients treated with incretin mimetic drugs, such as Januvia.
Related Articles:
FDA Approves Bydureon Despite Suspected Links to Thyroid Cancer
FDA Investigates Possible Link Between Bydureon and Pancreatitis
The U.S. Food and Drug Administration is reviewing reports by academic researchers that infer pre-cancerous cell changes may be associated with type-2 diabetes medications.
Bydureon contains a black box warning for the risk of an increase in medullary thyroid carcinoma and pancreatitis. The U.S. Food and Drug Administration has continued to monitor Bydureon and its side effects. The drug has caused lab rats to developtumors of the thyroid gland.
Related Drugs:
The suspicions and allegations surrounding Bydureon, Byetta, and similar durgs, have led to the FDA’s decision to investigate possible links between these medications, pancreatitis, and cancer.
Similar type-2 diabetes treatments (incretin mimetics) have also been linked to pancreatic cancer and adverse side effects. Lawsuits involve the development of pancreatitis, pancreatic cancer, and thyroid cancer. A motion was filed in April to consolidate lawsuits involving claims of pancreatic cancer linked to other incretin mimetics including Byetta, Januvia and Janumet. Currently there are 53 total plaintiffs who have filed personal injury lawsuits against any of these medications. As more patients come forward with pancreatic complications, the lawsuits are expected to increase.
